Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Ryvu Therapeutics S.A.
Sponsor

Ryvu Therapeutics S.A.

Poland Ul. Leona Henryka Sternbacha 2, 30-394 Cracow, Poland

About the sponsor

Ryvu Therapeutics S.A. is active in clinical research for acute myeloid leukemia, including disease settings with and without NPM1 mutation, as well as high-risk myelodysplastic syndrome. Its studies also extend to relapsed or refractory aggressive B-cell non-Hodgkin lymphoma, reflecting a strong focus on difficult-to-treat blood cancers.

  • Acute myeloid leukemia
  • High-risk myelodysplastic syndrome
  • Aggressive B-cell non-Hodgkin lymphoma

The sponsor’s hematology portfolio includes both standalone and combination-based therapeutic development in advanced relapsed or refractory disease.

About Specializations

Ryvu Therapeutics S.A. runs clinical trials in conditions such as Acute myeloid leukaemia, Myelofibrosis, Myelodysplastic syndrome, Neoplasm, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

6 clinical trials

Myelofibrosis+3

Recruiting

Study of RVU120 treatment in patients with myelodysplastic syndrome, solid tumors, or acute myeloid leukemia who benefited from previous RVU120 therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Ryvu Therapeutics S.A.

Acute myeloid leukaemia

Recruiting

Study on RVU120 and Venetoclax for Patients with Acute Myeloid Leukemia After Previous Treatment Failure

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Ryvu Therapeutics S.A.

B-cell lymphoma recurrent+1

Recruiting

Study of MEN1703 and Glofitamab for Patients with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:Ryvu Therapeutics S.A.

Myelofibrosis

Not recruiting

Study of RVU120 and Ruxolitinib for Patients with Intermediate or High-Risk Myelofibrosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Ryvu Therapeutics S.A.

Acute myeloid leukaemia+1

Not recruiting

Study of RVU120 for Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
  • Sponsor:Ryvu Therapeutics S.A.

Neoplasm

Not recruiting

Study of RVU120 for Patients with Advanced Solid Tumors After Standard Treatments Have Failed

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
  • Sponsor:Ryvu Therapeutics S.A.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.